

Sunday, March 18 - Thursday, March 22

New Orleans, LA

American Chemical Society National Meeting 2018

President and CEO, [Christopher J. Burns, Ph.D.](#), will present Venatorx Pharmaceuticals' lead clinical antibacterial candidate, [VNRX-5133](#), during the First-Time Disclosure of Clinical Candidates Symposium on Wednesday, March 21, 2018 at 3:15pm CT in the La Nouvelle Orleans Ballrooms A/B at the Ernest N. Morial Convention Center in New Orleans, LA.

The [oral presentation](#) is entitled, “Discovery of VNRX-5133: A broad-spectrum serine- and metallo-beta-lactamase inhibitor (BLI) for [carbapenem-resistant bacterial infections](#) (“superbugs”).”

VNRX-5133 is a new-generation BLI with unique broad-spectrum activity, covering both serine- and metallo-beta-lactamases. VenatoRx is developing VNRX-5133 in a fixed combination with the 4th generation cephalosporin, cefepime, to provide a best-in-class treatment option for infections caused by multi-drug resistant (MDR) gram-negative bacteria, including: carbapenem-resistant Enterobacteriaceae (CRE) and *Pseudomonas aeruginosa*; suspected polymicrobial infections caused by both gram-negative and gram-positive pathogens; and bioterror pathogens such as *Burkholderia spp.* and *Salmonella spp.*

This project has been funded in whole or in part with Federal funds from the National Institute for Allergy and Infectious Diseases, [National Institutes of Health](#), Department of Health and Human Services, under Contract No. HHSN272201300019C, and [Wellcome Trust](#) under Award No. 360G-Wellcome-101999/Z/13/Z.